Physician profile
Dasul Jin
NPI 1336608264
$2,016.16
in general payments reported to CMS, 2019-2025
22 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.74 · 2021: $232 · 2022: $471 · 2023: $211 · 2024: $591 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $341.19 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Abbvie INC. | $283.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.41 | 2021-2025 | Wainua |
| Emd Serono, INC. | $181.11 | 2021-2023 | Mavenclad |
| Genentech USA, INC. | $176.03 | 2022-2024 | Ocrevus, Enspryng |
| Genzyme Corporation | $152.04 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $146.85 | 2019-2024 | Ultomiris |
| Pfizer INC. | $84.17 | 2024-2025 | |
| Horizon Therapeutics Plc | $64.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.14 | 2022 | |
| Vanda Pharmaceuticals INC. | $52.49 | 2025 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $46.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.95 | 2023-2024 | Epidiolex |
| Lilly USA, LLC | $36.66 | 2024 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $27.69 | 2025 | Vyvgart Hytrulo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.06 | 2021 | |
| Tg Therapeutics, INC. | $20.24 | 2023 | |
| Springworks Therapeutics, INC. | $19.28 | 2025 | Gomekli |
| Averitas Pharma INC. | $17.20 | 2024 | Qutenza |
| Celgene Corporation | $16.60 | 2021 | |
| Neurelis, INC. | $13.89 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $13.88 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dasul Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.